Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
NCT07308886
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
55
Enrollment
NIH
Sponsor class
Conditions
Kaposi Sarcoma
Interventions
DRUG:
CYT107
Sponsor
National Cancer Institute (NCI)